Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in medullary thyroid cancer
NCT00410761Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2006
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in Medullary Thyroid Cancer (MTC) comparing Placebo with Vandetanib (2 arms). Primary endpoint: Progression-Free Survival. Started Nov 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT00410761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410761.